Search
Menu
Home
HTB
2024
August
HTB
August 2024
Contents
Conference reports
AIDS 2024: Ten early reports
Five days on two days off: Biktarvy in pilot FOTO study
Subcutaneous formulation of long-acting CAB/RPV discontinued
First data on third-generation integrase inhibitor from ViiV
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
Antiretrovirals
BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024
mpox (monkeypox)
Responses to mpox clade 1b emergency
WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study
HTB RSS
Current issues
August 2024
July 2024
June 2024
Back issues
Special report
Uganda Court rejects appeal against the LGBTQ+ hate law
5 April 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage